Literature DB >> 15129982

Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin.

R J Babu1, J K Pandit.   

Abstract

Bupranolol (BPL) is a potent beta-blocking agent, the extensive first-pass metabolism (>90%) and rapid elimination half-life (1.5-2.0 h) of this drug make it well suited to be developed as a transdermal delivery system (TDS). Hydroxypropyl betaCD (HPbetaCD) and partially methylated betaCD (PMbetaCD) were used as penetration enhancers for BPL. The formation of inclusion complex of BPL with these cyclodextrins (CDs) was characterized in solution and solid states by phase solubility, X-ray diffractometry and differential scanning calorimetry (DSC) analyses. The effect of CDs on the permeation enhancement of BPL through rat skin was studied using side-by-side diffusion cells and pH 7.4 phosphate-buffered saline (PBS). CDs were employed at different concentrations with 0.4% (w/v) BPL as well as with excess quantity of BPL (1.0%, w/v) that CDs could not complex all the BPL and the drug was in the form of an aqueous suspension. The permeation of BPL from its aqueous suspension (0.4%, w/v) significantly increased when CDs were used at low concentrations (up to 2 and 5%, w/v concentration for HPbetaCD and PMbetaCD, respectively) (P < 0.01). At higher CD concentrations, the permeation of BPL decreased; and both CDs at 10% (w/w), showed similar flux values to that of control (no enhancer, P > 0.05). The permeation of BPL from its 1.0% (w/v) aqueous suspension increased with increase in concentration of CD up to 10% (w/v) for HPbetaCD and PMbetaCD. At 10% (w/v) concentration of HPbetaCD and PMbetaCD, the flux of BPL from its 1.0% aqueous suspension increased 3.8- and 4.6-fold (P < 0.01 and P < 0.001, respectively). The permeation data of skin pretreatment with CDs indicate that HPbetaCD had no effect on the skin, whereas PMbetaCD significantly reduced the skin barrier for BPL, as shown by 1.7-fold increase in the flux by PMbetaCD pretreatment (P < 0.001). Overall, both HPbetaCD and PMbetaCD were found to be suitable for improving the solubility and penetration enhancement of BPL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15129982     DOI: 10.1016/j.ijpharm.2003.11.004

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Molecular inclusion complex of curcumin-β-cyclodextrin nanoparticle to enhance curcumin skin permeability from hydrophilic matrix gel.

Authors:  Heni Rachmawati; Citra Ariani Edityaningrum; Rachmat Mauludin
Journal:  AAPS PharmSciTech       Date:  2013-08-29       Impact factor: 3.246

2.  Transdermal delivery of cyclodextrin-solubilized curcumin.

Authors:  Raksha Ghanghoria; Prashant Kesharwani; Hrushikesh Bharat Agashe; N K Jain
Journal:  Drug Deliv Transl Res       Date:  2013-06       Impact factor: 4.617

3.  Effect of cyclodextrins on the complexation and nasal permeation of melatonin.

Authors:  R Jayachandra Babu; Pankaj Dayal; Mandip Singh
Journal:  Drug Deliv       Date:  2008-08       Impact factor: 6.419

4.  Nanoemulgel, an Innovative Carrier for Diflunisal Topical Delivery with Profound Anti-Inflammatory Effect: in vitro and in vivo Evaluation.

Authors:  Mehreen Bashir; Junaid Ahmad; Muhammad Asif; Salah-Ud-Din Khan; Muhammad Irfan; Asim Y Ibrahim; Sajid Asghar; Ikram Ullah Khan; Muhammad Shahid Iqbal; Abdul Haseeb; Syed Haroon Khalid; Mohammed As Abourehab
Journal:  Int J Nanomedicine       Date:  2021-02-22

5.  Transdermal Co-Delivery of Urea and Recombinant Human Growth Hormone.

Authors:  Leila Shams; Mahvash Khodabandeh Shahraky; Mona Sadat Mirtaleb
Journal:  Iran J Biotechnol       Date:  2021-10-01       Impact factor: 1.671

6.  Improvement of Butamben Anesthetic Efficacy by the Development of Deformable Liposomes Bearing the Drug as Cyclodextrin Complex.

Authors:  Paola Mura; Francesca Maestrelli; Marzia Cirri; Giulia Nerli; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Natascia Mennini
Journal:  Pharmaceutics       Date:  2021-06-12       Impact factor: 6.321

Review 7.  Systemic delivery of β-blockers via transdermal route for hypertension.

Authors:  Abdul Ahad; Fahad I Al-Jenoobi; Abdullah M Al-Mohizea; Naseem Akhtar; Mohammad Raish; Mohd Aqil
Journal:  Saudi Pharm J       Date:  2014-01-03       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.